Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...
A Novo Nordisk challenge has driven a Pennsylvania-based telehealth company to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of pessimism is justified, the current market cap is way to low considering ...
Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease (AD). But perhaps the larger story associated with the unsurprising result is the market ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Elaine Chen covers biotech, co-writes The Readout newsletter, and ...
Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of ...
Novo Nordisk said a weight-loss drug candidate helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company. The Danish ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
Amycretin targets GLP-1 and amylin hormones, seen as potential best-in-class therapy Novo shares rise over 5% after amycretin trial results Amycretin aids significant weight loss and glucose control ...
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...
SAN DIEGO Dec 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback